Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy.
June 10, 2026 06:37 AM EDT
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Sanofi stops immune drug trial in latest research setback
Sanofi encerra estudo de fase avançada de medicamento experimental
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sanofi (NASDAQ:SNY)
"Je me considère comme un phénix" : un nouveau traitement permet de ralentir la progression de la sclérose en plaques
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Novartis
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
A farmacêutica francesa declarou que avaliará se dará continuidade a outros estudos em andamento para o fármaco, chamado…
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst…
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
En avril, les autorités sanitaires européennes ont approuvé la mise sur le marché d'un médicament de Sanofi, qui permet de lutter…
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine, pociredir for sickle cell disease, after feedback from the…
